查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1716781

細胞和基因治療製造服務市場按服務類型、技術類型、治療領域、應用和最終用戶分類——2025 年至 2030 年全球預測

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計細胞和基因治療製造服務市場在 2023 年的價值將達到 173.3 億美元，到 2024 年將以 15.81% 的複合年成長率成長至 199.8 億美元，到 2030 年將達到 484.4 億美元。

主要市場統計數據
基準年2023年 173.3億美元
預計年份：2024年 199.8億美元
預測年份 2030 484.4億美元
複合年成長率（%） 15.81%

在當今快速發展的環境中，細胞和基因治療製造業處於改變現代醫學的前沿。在前所未有的科學突破和解決複雜疾病的迫切需求的推動下，這個市場具有動態創新和轉型潛力的特徵。該部門的製造服務旨在確保新型治療方法以安全、高效和可擴展的方式從研究轉向臨床應用。隨著技術的不斷進步和法規環境的加強，該領域的公司不斷改進其方法，以滿足全球對優質治療解決方案日益成長的需求。

我們的製造商投資最先進的設備並實施最尖端科技，以在整個生產過程中保持卓越的品質。隨著公共和私營部門更加重視個人化醫療，對細胞和基因治療技術的投資達到了歷史最高水準。這份全面的概述探討了最重要的行業趨勢，並提供了深入的見解以幫助進行策略規劃，鼓勵相關人員適應並在競爭激烈的市場環境中取得成功。

該內容結合了廣泛的研究和先進的分析方法，提供了有關製造能力和市場趨勢的重要背景和清晰度。學術界、委外研發機構和大型製藥企業之間的合作凸顯了尋求創新解決方案的緊迫性，它們都為產業成長和發展的強大生態系統做出了貢獻。在這種背景下，製造服務對於向世界各地的患者提供創新的臨床解決方案至關重要。

改變細胞和基因治療製造服務市場

細胞和基因治療製造業正在經歷一場變革性轉變，這場轉變正在重塑產業範式並推動快速進步。在過去的幾年中，治療方法開發、製造和分銷的根本性質已經發生了徹底的改變，從傳統的生技藥品製造轉向高度專業化的治療平台。公司正在利用創新技術、先進的自動化和數位整合來簡化製造流程、確保一致性並提高整體安全性。隨著這些開創性療法的出現，監管審查也越來越嚴格，對數據完整性、可重複性和品管的要求也越來越高，這也推動了這種轉變。

流程開發的持續創新正在突破可擴展性和效率的界限。製造商目前面臨的挑戰是同時滿足小批量臨床生產和大規模商業製造要求。隨著技術整合變得越來越主流，流程變得越來越適應量身定做的治療方法，體現了個人化護理所需的靈活性。此外，生物技術公司、學術研究機構和監管機構之間的策略聯盟與合作極大地促進了技術轉移和知識共用，從而產生了更靈活的製造方法。

從引入高性能篩檢方法到採用強大的品管框架，該領域的技術力正在迅速擴展。隨著幹細胞研究和基因編輯方法的進步，對個人化研究的需求不斷增加，該行業正在走向更有效率、可靠和可擴展的製造模式。這些轉型轉變凸顯了該產業向先進創新網路的演變，其中卓越的營運對於維持成長和改善全球患者的治療效果至關重要。

差異化市場分析的關鍵細分洞察

透過考慮市場區隔的各個方面，可以理解細胞和基因治療製造服務的複雜性。服務類型是分析的主要驅動力，因為市場研究涉及分析和品管服務、細胞庫服務、諮詢服務、填充和完成服務、GMP 製造服務、流程開發服務、監管支援服務、供應鏈和物流服務、技術轉移服務和載體製造服務等類別。每項服務都發揮著至關重要的作用，確保治療達到最高標準，同時保持高效的生產計劃。

除了基於服務的細分之外，技術細微差別對於理解市場成長動態也至關重要。經過深入分析，技術格局分為基因編輯技術和載體技術。在基因編輯方面，CRISPR/Cas9、轉錄活化因子樣效應核酸酶和鋅指核酸酶等平台可以精確修改基因組結構，有助於改善治療效果。載體技術進一步分為非病毒平台和病毒平台。非病毒載體系統包括陽離子脂質、幾丁聚醣基載體、樹狀聚合物、無機奈米顆粒、脂質體、裸露DNA/RNA、肽基載體和聚合物載體，因其安全性和可擴展性而受到高度重視。相反，病毒載體則被視為腺結合病毒載體、腺病毒載體、單純皰疹病毒載體和逆轉錄病毒載體，每種載體在轉導效率和靶向遞送方面都具有獨特的優勢。

透過在心血管疾病、感染疾病、一次性疾病和腫瘤學的背景下分析市場，治療細分增加了另一層洞察力。心血管疾病中的冠狀動脈疾病和心臟衰竭，感染疾病中的乙肝和愛滋病毒，以及一次性疾病中的囊腫纖維化、血友病和鐮狀細胞性貧血等特定疾病，體現了對小眾疾病領域的深入關注。本文也深入回顧了腫瘤學，並專注於骨髓惡性腫瘤和固態腫瘤。根據應用和治療領域進行細分，臨床製造與商業製造有所區別，每種製造都需要自己的營運策略和品質保證通訊協定。

透過將市場細分為受託研究機構、醫院診所、製藥和生物技術公司、研究機構和學術機構等，最終用戶分析進一步豐富了分析框架。這種細分框架使相關人員和決策者能夠細緻地了解每個細分市場的獨特行為、需求和成長前景，從而能夠更有針對性地制定策略並有效地配置資源。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 慢性病和遺傳性疾病盛行率上升
      • 增加政府對先進治療方法研發的經費與津貼
    • 限制因素
      • 細胞和基因治療製造相關的高營運成本
    • 機會
      • CRISPR 技術的廣泛應用為基因工程服務創造了新的成長軌跡
      • 生物加工設備的技術進步為高效生產過程鋪平了道路
    • 任務
      • 細胞和基因治療製造中的品管和污染問題
  • 市場區隔分析
    • 服務類型：需要提供安全儲存和存取各種細胞株的細胞銀行服務
    • 技術類型：病毒載體增殖，實現高轉染效率和穩定的基因表現
    • 治療領域：細胞和基因治療在腫瘤學中治療造血系統惡性腫瘤和固態腫瘤的意義
    • 用途：使用臨床製造進行臨床前和臨床測試
    • 最終用戶：製藥和生物技術公司擴大採用該技術來開發和商業化創新治療方法
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 細胞和基因治療製造服務市場（按服務類型）

  • 介紹
  • 分析和品管服務
  • 細胞銀行服務
  • 諮詢服務
  • 灌裝和精加工服務
  • GMP生產服務
  • 製程開發服務
  • 監管支援服務
  • 供應鍊和物流服務
  • 技術轉移服務
  • 向量創建服務

7. 細胞和基因治療製造服務市場（依技術類型）

  • 介紹
  • 基因編輯
    • CRISPR/Cas9
    • 轉錄活化因子樣效應核酸酶
    • 鋅指核酸酶
  • 向量
    • 非病毒載體
      • 陽離子脂質
      • 幾丁聚醣載體
      • 樹狀聚合物
      • 無機奈米粒子
      • 脂質體
      • 裸露的DNA/RNA
      • 基於胜肽的載體
      • 聚合物載體
    • 病毒載體
      • 腺結合病毒（AAV）載體
      • 腺病毒載體
      • 單純皰疹病毒（HSV）載體
      • 逆轉錄病毒載體

第8章細胞和基因治療製造服務市場（按治療領域）

  • 介紹
  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞性貧血
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤

第9章細胞和基因治療製造服務市場（按應用）

  • 介紹
  • 臨床製造
  • 商業製造

第 10 章細胞和基因治療製造服務市場（按最終用戶）

  • 介紹
  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究和學術機構

11.美洲細胞與基因治療製造服務市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太細胞與基因治療製造服務市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲細胞和基因治療製造服務市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Advanced BioScience Laboratories, Inc. by Institut Merieux
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth BIoTechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi BIoTec BV & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS SA
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.33 billion in 2023 and is projected to grow to USD 19.98 billion in 2024, with a CAGR of 15.81%, reaching USD 48.44 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 17.33 billion
Estimated Year [2024] USD 19.98 billion
Forecast Year [2030] USD 48.44 billion
CAGR (%) 15.81%

In today's rapidly evolving landscape, the cell and gene therapy manufacturing sector is at the forefront of revolutionizing modern medicine. Driven by unprecedented scientific breakthroughs and an urgent need to address complex diseases, this market is characterized by its dynamic innovation and transformative potential. The manufacturing services in this sector are designed to ensure that emerging therapies progress from research to clinical application in safe, efficient, and scalable ways. With constant technological advancements and a robust regulatory environment, companies in this field are continually refining their methods to meet increasing global demand for high-quality therapeutic solutions.

Manufacturers are investing in state-of-the-art facilities and integrating cutting-edge technology to maintain superior quality throughout the production process. As both the private and public sectors place greater emphasis on personalized healthcare, investment in cell and gene therapy technology has never been higher. This comprehensive summary explores the most significant industry trends and provides detailed insights that are instrumental for strategic planning, urging stakeholders to adapt and thrive in a competitive market landscape.

By combining extensive research with advanced analytical methodologies, the content here offers essential context, background, and clarity regarding manufacturing capabilities and market trends. The urgency for innovative solutions is underscored by collaborations between academia, contract research organizations, and large pharmaceutical companies, each contributing to a robust ecosystem of industry growth and development. In this context, the role of manufacturing services is pivotal to the delivery of transformative clinical solutions to patients around the world.

Transformative Shifts in the Cell & Gene Therapy Manufacturing Landscape

The cell and gene therapy manufacturing sector is experiencing transformative shifts that are reshaping the industry paradigm and driving rapid advancements. Over the past several years, the fundamental nature of how therapies are developed, produced, and distributed has undergone a complete overhaul, marking a transition from traditional biologics manufacturing to highly specialized therapeutic platforms. Companies are harnessing innovative technologies, advanced automation, and digital integration to streamline production processes, ensure consistency, and improve overall safety. This transformation is also spurred by the heightened regulatory scrutiny that now accompanies these pioneering treatments, with regulators demanding higher levels of data integrity, reproducibility, and quality control.

Continuous innovation in process development is pushing the boundaries of scalability and efficiency. Manufacturers are now challenged to accommodate small-batch clinical production alongside large-scale commercial manufacturing requirements. As technological integration becomes mainstream, processes are increasingly becoming adaptable to a tailored therapeutic approach, embodying flexibility that is necessary for personalized treatments. Additionally, strategic partnerships and collaborations between biotech companies, academic research institutions, and regulatory bodies have significantly expedited technology transfer and knowledge sharing, which in turn have led to more agile production practices.

From the incorporation of high-throughput screening methods to the adoption of robust quality control frameworks, the sector's technological capability is expanding rapidly. As the demand for personalized therapies grows in tandem with advancements in stem cell research and gene editing methodologies, the industry is charting a course towards more efficient, reliable, and scalable manufacturing models. These transformative shifts underscore the sector's evolution into a sophisticated network of innovation where operational excellence is critical for sustaining growth and improving patient outcomes worldwide.

Key Segmentation Insights for a Differentiated Market Analysis

The intricacies of cell and gene therapy manufacturing services can be understood by examining the various dimensions through which the market has been segmented. Service types are a primary driver for analysis, as the market is examined across categories such as analytical and quality control services, cell banking services, consulting services, fill and finish services, GMP manufacturing services, process development services, regulatory support services, supply chain and logistics services, technology transfer services, and vector production services. Each of these service offerings plays a crucial role in ensuring that therapies are produced to the highest possible standards while maintaining efficient production timelines.

In addition to service-based segmentation, technological nuances are integral to deciphering the market's growth dynamics. A thorough analysis divides the technological landscape into gene editing and vector technologies. Within gene editing, platforms such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases are instrumental in allowing precise modifications in the genomic structure, thereby enhancing therapy outcomes. Vector technologies are further dissected into non-viral and viral platforms. Non-viral vector systems, which include cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, are celebrated for their safety profile and scalability. Conversely, viral vectors are examined through the lens of adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, each offering unique advantages in terms of transduction efficiency and targeted delivery.

Therapeutic area segmentation provides another layer of insight, with the market being analyzed in the contexts of cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Specific conditions such as coronary artery disease and heart failure within cardiovascular diseases, hepatitis B and HIV within infectious diseases, and cystic fibrosis, hemophilia, and sickle cell anemia among monogenic disorders illustrate the detailed focus on niche disease areas. Oncology is also meticulously reviewed, with attention distributed between hematological malignancies and solid tumors. Beyond therapeutic divisions, a further segmentation based on application distinguishes between clinical manufacturing and commercial manufacturing, each necessitating its own set of operational strategies and quality assurance protocols.

Profiling based on end-user further enriches the analytical framework, as the market is segmented across contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic institutions. This segmentation framework empowers stakeholders and decision-makers by providing a nuanced understanding of each market segment's unique behaviors, needs, and growth prospects, thereby enabling more targeted strategy formulations and effective resource allocation.

Based on Service Type, market is studied across Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services.

Based on Technology Type, market is studied across Gene Editing and Vectors. The Gene Editing is further studied across CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases. The Vectors is further studied across Non-Viral Vectors and Viral Vectors. The Non-Viral Vectors is further studied across Cationic Lipids, Chitosan-Based Vectors, Dendrimers, Inorganic Nanoparticles, Liposomes, Naked DNA/RNA, Peptide-Based Vectors, and Polymeric Vectors. The Viral Vectors is further studied across Adeno-Associated Virus (AAV) Vectors, Adenovirus Vectors, Herpes Simplex Virus (HSV) Vectors, and Retrovirus Vectors.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Monogenic Disorders, and Oncology. The Cardiovascular Diseases is further studied across Coronary Artery Disease and Heart Failure. The Infectious Diseases is further studied across Hepatitis B and HIV. The Monogenic Disorders is further studied across Cystic Fibrosis, Hemophilia, and Sickle Cell Anemia. The Oncology is further studied across Hematological Malignancies and Solid Tumors.

Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.

Based on End-User, market is studied across Contract Research Organizations, Hospitals & Clinics, Pharmaceutical & Biotech Companies, and Research Institutes & Academic Institutions.

Regional Insights: Assessing the Global Market Landscape

Analyzing the market through a global lens reveals distinctive trends and competitive dynamics across various regions. In the Americas, advanced infrastructure, a conducive regulatory environment, and a robust network of clinical research institutions are creating a fertile ground for the adoption and scaling of cell and gene therapy technologies. Market participants in this region benefit from a strong focus on innovation supported by well-funded academic and private research initiatives, which continuously drive breakthrough developments.

The combined territory of Europe, the Middle East, and Africa has emerged as a vital hub for both innovation and regulatory prowess. In Europe, rigorous standards enforced by regulatory bodies have led to the development of high-quality manufacturing practices, ensuring that therapies adhere to the most stringent safety protocols. Meanwhile, emerging markets within the Middle East and Africa are progressively investing in state-of-the-art manufacturing facilities and seeking collaborations with global industry leaders to uplift their capabilities and expertise in cell and gene therapy production.

Asia-Pacific has become a powerhouse in the global pharmaceutical landscape, largely due to its rapid economic growth, increased investment in technology, and an accelerating pace of regulatory harmonization. Countries in this region are strategically focused on enhancing their capabilities in both clinical and commercial manufacturing, which is attracting substantial foreign investments and forging strategic alliances with international manufacturers. Such regional insights illustrate that while each region exhibits its own distinct set of opportunities and challenges, the overarching trend is one of collaborative growth and robust market expansion worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders: A Deep Dive into Key Company Performance Drivers

A critical component of uncovering emerging trends in the cell and gene therapy manufacturing space involves a close examination of the actions and performance of key companies. Research and development efforts by entities such as Advanced BioScience Laboratories, Inc. by Institut Merieux and AGC Biologics have set the benchmark for quality and innovation across the industry. Companies including AmplifyBio, Bio-Techne Corporation, and C.H. Boehringer Sohn AG & Co. KG have further contributed to the progression of manufacturing technologies through advanced analytical capabilities and seamless integration of quality control systems.

Other market leaders such as Catalent, Inc. and Cell Therapies Pty Ltd. are not only enhancing process optimization but are also pioneering breakthroughs in cell banking and process development strategies. Firms like Cell-Easy and Charles River Laboratories International, Inc. have become synonymous with reliable supply chain management that supports wide-ranging production demands. The strategic insights from heavyweight players such as Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, and Genezen Laboratories, Inc. exemplify the drive towards harnessing next-generation manufacturing technologies to ensure sustained growth.

The presence of major corporations like Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, and Miltenyi Biotec B.V. & Co. KG further reinforces industry confidence by demonstrating long-standing expertise in optimizing and scaling manufacturing processes. In addition, influential market players such as Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, and ProPharma Group Holdings, LLC have seamlessly integrated innovative systems that optimize quality, compliance, and production throughput. Strategic insights offered by companies like Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd. highlight the importance of effort in aligning technological advancements with operational efficiency. Collectively, these key companies set a robust foundation for the sector by championing rigorous quality standards and embracing innovation at every stage of the product lifecycle.

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc. by Institut Merieux, AGC Biologics, AmplifyBio, Bio-Techne Corporation, C.H. Boehringer Sohn AG & Co. KG, Catalent, Inc., Cell Therapies Pty Ltd., Cell-Easy, Charles River Laboratories International, Inc., Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, Genezen Laboratories, Inc., Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, ProPharma Group Holdings, LLC, Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to leverage emerging trends by embracing collaborative innovation and agile manufacturing protocols to remain competitive in an increasingly complex market. It is recommended to invest in advanced technological platforms for process optimization that not only reduce production time but also enhance product quality and consistency. Leaders should prioritize the adoption of digitalization solutions, including data analytics and automation, to streamline validation processes and improve overall operational efficiency. By integrating these systems, companies can foresee challenges in real-time and achieve a more responsive manufacturing ecosystem.

Furthermore, fostering robust partnerships with regulatory bodies enables a proactive approach in aligning production standards with evolving global requirements. This can be achieved by developing comprehensive training programs that ensure staff remains adept at utilizing cutting-edge technology while adhering to stringent quality control measures. A renewed focus on technology transfer and strategic collaborations across cross-functional teams will also help in bridging the gap between clinical research and commercial production capabilities. Furthermore, diversifying service portfolios by incorporating end-to-end manufacturing solutions can help cater to the varying needs of both clinical and commercial manufacturing segments.

Industry leaders must also consider environmental sustainability as an integral part of manufacturing excellence. Investing in green technologies and reducing resource wastage during production not only contributes to corporate responsibility but also enhances long-term operational viability. In conclusion, a multifaceted approach that intertwines process innovation, regulatory engagement, staff training, and sustainability investments will serve as the cornerstone for achieving both immediate and long-term success in the cell and gene therapy manufacturing domain.

Conclusion: Charting the Path Forward in Cell & Gene Therapy Manufacturing

In summary, the evolution of cell and gene therapy manufacturing services is marked by significant shifts that are transforming how therapies are developed and delivered. The integration of advanced technologies with rigorous quality control, the strategic segmentation of services, and the dynamic interplay among key market regions provide a detailed roadmap for industry advancement. The narrative outlined earlier reinforces that strategic agility, through innovative process development and regulatory alignment, is the cornerstone for remaining competitive. As the field continues to mature, organizations that adopt a forward-thinking approach will be best positioned to embrace new opportunities and overcome emerging challenges.

The collective insights presented in this review illuminate how meticulous segmentation and regional analysis are critical in mapping out growth strategies. Equally, the actions of leading companies offer invaluable benchmarks and best practices that can be replicated for enhanced production efficiency and market penetration. By uniting scientific innovation with strategic planning, the path forward becomes clearer, offering a promise of groundbreaking therapies that meet the urgent demands of healthcare across the globe. The consolidated message is one of resilience and proactive adaptation - qualities that are essential for transforming challenges into opportunities in an ever-changing regulatory and technological landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and genetic disorders
      • 5.1.1.2. Increase in government funding and grants for research and development of advanced therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High operational costs associated with cell & gene therapy manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of CRISPR technology providing a new growth trajectory in genetic engineering services
      • 5.1.3.2. Technological advancements in bioprocessing equipment create avenues for efficient production processes
    • 5.1.4. Challenges
      • 5.1.4.1. Quality control and contamination issues in cell & gene therapy production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Need for cell banking services for providing secure storage and access to various cell lines
    • 5.2.2. Technology Type: Proliferating usage of the viral vectors for their high transfection efficiency and stable gene expression
    • 5.2.3. Therapeutic Area: Significance of cell gene therapy in oncology for treating hematological malignancies and solid tumors
    • 5.2.4. Application: Utilization of clinical manufacturing to enable preclinical testing and clinical trials
    • 5.2.5. End-User: Rising adoption across pharmaceutical & biotech companies for the development and commercialization of innovative therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 6.1. Introduction
  • 6.2. Analytical & Quality Control Services
  • 6.3. Cell Banking Services
  • 6.4. Consulting Services
  • 6.5. Fill & Finish Services
  • 6.6. GMP Manufacturing Services
  • 6.7. Process Development Services
  • 6.8. Regulatory Support Services
  • 6.9. Supply Chain & Logistics Services
  • 6.10. Technology Transfer Services
  • 6.11. Vector Production Services

7. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Gene Editing
    • 7.2.1. CRISPR/Cas9
    • 7.2.2. Transcription Activator-Like Effector Nucleases
    • 7.2.3. Zinc Finger Nucleases
  • 7.3. Vectors
    • 7.3.1. Non-Viral Vectors
      • 7.3.1.1. Cationic Lipids
      • 7.3.1.2. Chitosan-Based Vectors
      • 7.3.1.3. Dendrimers
      • 7.3.1.4. Inorganic Nanoparticles
      • 7.3.1.5. Liposomes
      • 7.3.1.6. Naked DNA/RNA
      • 7.3.1.7. Peptide-Based Vectors
      • 7.3.1.8. Polymeric Vectors
    • 7.3.2. Viral Vectors
      • 7.3.2.1. Adeno-Associated Virus (AAV) Vectors
      • 7.3.2.2. Adenovirus Vectors
      • 7.3.2.3. Herpes Simplex Virus (HSV) Vectors
      • 7.3.2.4. Retrovirus Vectors

8. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
    • 8.2.1. Coronary Artery Disease
    • 8.2.2. Heart Failure
  • 8.3. Infectious Diseases
    • 8.3.1. Hepatitis B
    • 8.3.2. HIV
  • 8.4. Monogenic Disorders
    • 8.4.1. Cystic Fibrosis
    • 8.4.2. Hemophilia
    • 8.4.3. Sickle Cell Anemia
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors

9. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Manufacturing
  • 9.3. Commercial Manufacturing

10. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotech Companies
  • 10.5. Research Institutes & Academic Institutions

11. Americas Cell & Gene Therapy Manufacturing Services Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. OmniaBio revolutionizes cell & gene therapy manufacturing with AI-driven facility in Ontario,
    • 14.3.2. eXmoor Pharma and Virica Biotech are collaborating to enhance the manufacturing efficiency of adeno-associated vectors
    • 14.3.3. Strategic collaboration between SK pharmteco and Cryoport revolutionizes cell & gene therapy logistics and manufacturing
    • 14.3.4. eXmoor Pharma's MIA(IMP) license fuels expansion in GMP-grade cell & gene therapy manufacturing
    • 14.3.5. Cryoport and Minaris unite to revolutionize cell & gene therapy with integrated services
    • 14.3.6. Merck KGaA's acquisition of Mirus Bio enhances viral vector manufacturing for cell & gene therapies
    • 14.3.7. ProPharma and PBL collaborate on innovative cell & gene therapy manufacturing
    • 14.3.8. Memel Biotech revolutionizes cell & gene therapy manufacturing with new Klaipeda facility launch
    • 14.3.9. FUJIFILM invests USD 200 million to increase cell therapy CDMO capabilities amid market surge
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Charles River Laboratories International, Inc.
    • 14.4.2. Lonza Group AG
    • 14.4.3. Takara Bio Inc.
    • 14.4.4. Merck KGaA

Companies Mentioned

  • 1. Advanced BioScience Laboratories, Inc. by Institut Merieux
  • 2. AGC Biologics
  • 3. AmplifyBio
  • 4. Bio-Techne Corporation
  • 5. C.H. Boehringer Sohn AG & Co. KG
  • 6. Catalent, Inc.
  • 7. Cell Therapies Pty Ltd.
  • 8. Cell-Easy
  • 9. Charles River Laboratories International, Inc.
  • 10. Danaher Corporation
  • 11. eXmoor Pharma Concepts Limited
  • 12. FUJIFILM Diosynth Biotechnologies
  • 13. Genezen Laboratories, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Lonza Group AG
  • 16. Merck KGaA
  • 17. Miltenyi Biotec B.V. & Co. KG
  • 18. Minaris Regenerative Medicine GmbH by Resonac Corporation
  • 19. Nikon Corporation
  • 20. Novartis AG
  • 21. Oxford Biomedica PLC
  • 22. ProPharma Group Holdings, LLC
  • 23. Recipharm AB
  • 24. Samsung Biologics Co., Ltd.
  • 25. SGS S.A.
  • 26. STEMCELL Technologies Inc.
  • 27. Takara Bio Inc.
  • 28. Thermo Fisher Scientific Inc.
  • 29. uBriGene Biosciences Inc.
  • 30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-CURRENCY
  • FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
  • FIGURE 4. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 124. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 166. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 168. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 170. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 172. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 178. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 179. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 180. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 181. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 191. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 192. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 193. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 194. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 195. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 196. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 197. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 198. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 204. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 205. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 206. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 207. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 208. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 209. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 217. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 218. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 219. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 220. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 230. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 231. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 232. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 233. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 234. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 243. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 244. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 245. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 246. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 247. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 248. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 249. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 250. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 256. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 257. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 258. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 259. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 260. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 261. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 262. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 263. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
  • TABLE 269. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
  • TABLE 270. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 271. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
  • TABLE 272. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC